open access

Vol 81, No 1 (2023)
Expert opinion
Published online: 2023-01-24
Get Citation

Management of valvular heart disease in patients with cancer: Multidisciplinary team, cancer-therapy related cardiotoxicity, diagnosis, transcatheter intervention, and cardiac surgery. Expert opinion of the Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and Working Group on Cardiac Surgery of the Polish Cardiac Society

Edyta Płońska-Gościniak1, Grzegorz Piotrowski2, Wojciech Wojakowski3, Piotr Gościniak4, Maria Olszowska56, Maciej Lesiak7, Aneta Klotzka7, Marek Grygier7, Marek Deja8, Jarosław D Kasprzak9, Tomasz Kukulski10, Wojciech Kosmala11, Piotr Suwalski12, Maciej Kolowca13, Kazimierz Widenka13, Tomasz Hryniewiecki14
DOI: 10.33963/KP.a2023.0023
·
Pubmed: 36641646
·
Kardiol Pol 2023;81(1):82-101.
Affiliations
  1. Department of Cardiology, Pomeranian Medical University, Szczecin, Poland
  2. Department of Cardiology, Nicolaus Copernicus Memorial Hospital Łódź, Poland & Cardio-oncology Department, Medical University of Lodz, Łódź, Poland
  3. Department of Cardiology and Structural Heart Diseases Medical University of Silesia, Katowice, Poland
  4. Laboratory of Non-Invasive Cardiac Imaging and Cardiooncology & Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin, Poland
  5. Department of Cardiac and Vascular Diseases, Institute of Cardiology & Department of Social Cardiology Institute of Cardiology, Jagiellonian University Medical College, Kraków
  6. John Paul II Hospital, Kraków, Poland
  7. 1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland
  8. Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland
  9. 1st Department of Cardiology, Medical University of Lodz, Łódź, Poland
  10. 2nd Department of Cardiology, Medical University of Silesia, Katowice Poland, Spec. Hospital, Zabrze, Poland
  11. Department of Cardiovascular Imaging, Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland
  12. Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and Administration, Warszawa, Poland
  13. Department of Cardiac Surgery, University of Rzeszow, Rzeszów, Poland
  14. Department of Valvular Heart Disease, National Institute of Cardiology, Warszawa, Poland

open access

Vol 81, No 1 (2023)
Expert opinion and position paper
Published online: 2023-01-24

Abstract

The Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and the Working Group on CardiacSurgery of the Polish Cardiac Society have released a position statement on risk factors, diagnosis, and management of patients with cancer and valvular heart disease (VHD). VHD can occur in patients with cancer in several ways, for example, it can exist or be diagnosed before cancer treatment, after cancer treatment, be an incidental finding during imaging tests, endocarditis related to immunosuppression, prolonged intravenous catheter use, or combination treatment, and nonbacterial thrombotic endocarditis. It is recommended to employ close cardiac surveillance for patients at high risk of complications during and after cancer treatment and for cancer treatments that may be cardiotoxic to be discussed by a multidisciplinary team. Patients with cancer and pre-existing severe VHD should be managed according to the 2021 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for VHD management, taking into consideration cancer prognosis and patient preferences.

Abstract

The Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and the Working Group on CardiacSurgery of the Polish Cardiac Society have released a position statement on risk factors, diagnosis, and management of patients with cancer and valvular heart disease (VHD). VHD can occur in patients with cancer in several ways, for example, it can exist or be diagnosed before cancer treatment, after cancer treatment, be an incidental finding during imaging tests, endocarditis related to immunosuppression, prolonged intravenous catheter use, or combination treatment, and nonbacterial thrombotic endocarditis. It is recommended to employ close cardiac surveillance for patients at high risk of complications during and after cancer treatment and for cancer treatments that may be cardiotoxic to be discussed by a multidisciplinary team. Patients with cancer and pre-existing severe VHD should be managed according to the 2021 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for VHD management, taking into consideration cancer prognosis and patient preferences.

Get Citation

Keywords

cardiooncology, cancer, cancer therapy related cardiotoxicity, cardiovascular imaging, valvular heart disease

About this article
Title

Management of valvular heart disease in patients with cancer: Multidisciplinary team, cancer-therapy related cardiotoxicity, diagnosis, transcatheter intervention, and cardiac surgery. Expert opinion of the Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and Working Group on Cardiac Surgery of the Polish Cardiac Society

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 81, No 1 (2023)

Article type

Expert opinion

Pages

82-101

Published online

2023-01-24

Page views

183

Article views/downloads

18

DOI

10.33963/KP.a2023.0023

Pubmed

36641646

Bibliographic record

Kardiol Pol 2023;81(1):82-101.

Keywords

cardiooncology
cancer
cancer therapy related cardiotoxicity
cardiovascular imaging
valvular heart disease

Authors

Edyta Płońska-Gościniak
Grzegorz Piotrowski
Wojciech Wojakowski
Piotr Gościniak
Maria Olszowska
Maciej Lesiak
Aneta Klotzka
Marek Grygier
Marek Deja
Jarosław D Kasprzak
Tomasz Kukulski
Wojciech Kosmala
Piotr Suwalski
Maciej Kolowca
Kazimierz Widenka
Tomasz Hryniewiecki

References (70)
  1. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
  2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(36): 2768–2801.
  3. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020; 22(11): 1945–1960.
  4. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43(7): 561–632.
  5. Bendary A, Ramzy A, Bendary M, et al. Transcatheter aortic valve replacement in patients with severe aortic stenosis and active cancer: a systematic review and meta-analysis. Open Heart. 2020; 7(1): e001131.
  6. Marmagkiolis K, Monlezun DJ, Cilingiroglu M, et al. TAVR in Cancer Patients: Comprehensive Review, Meta-Analysis, and Meta-Regression. Front Cardiovasc Med. 2021; 8: 641268.
  7. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014; 15(10): 1063–1093.
  8. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013; 14(7): 611–644.
  9. Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2017; 18(3): 254–275.
  10. Lopez-Mattei JC, Yang EH, Ferencik M, et al. Cardiac computed tomography in cardio-oncology: primer. JACC CardioOncol. 2021; 3(5): 635–649.
  11. Jordan JH, Todd RM, Vasu S, et al. Cardiovascular magnetic resonance in the oncology patient. JACC Cardiovasc Imaging. 2018; 11(8): 1150–1172.
  12. Tarkin JM, Ćorović A, Wall C, et al. Positron emission tomography imaging in cardiovascular disease. Heart. 2020; 106(22): 1712–1718.
  13. Agha AM, Lopez-Mattei J, Donisan T, et al. Multimodality imaging in carcinoid heart disease. Open Heart. 2019; 6(1): e001060.
  14. Murbraech K, Wethal T, Smeland KB, et al. Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: a national cross-sectional study. JACC Cardiovasc Imaging. 2016; 9(3): 230–239.
  15. Boekel NB, Schaapveld M, Gietema JA, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys. 2016; 94(5): 1061–1072.
  16. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109(5): 1878–1886.
  17. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114(23): 2474–2481.
  18. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  19. Stewart MH, Jahangir E, Polin NM. Valvular Heart Disease in Cancer Patients: Etiology, Diagnosis, and Management. Curr Treat Options Cardiovasc Med. 2017; 19(7): 53.
  20. Groarke JD, Nguyen PL, Nohria A, et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014; 35(10): 612–623.
  21. Veinot JP. Pathology of inflammatory native valvular heart disease. Cardiovasc Pathol. 2006; 15(5): 243–251.
  22. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003; 42(4): 743–749.
  23. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1994; 30(1): 43–54.
  24. Armstrong GT, Joshi VM, Zhu L, et al. Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. J Clin Oncol. 2013; 31(6): 774–781.
  25. Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013; 26(9): 1013–1032.
  26. Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation-associated valvular disease. Am J Cardiol. 2003; 92(2): 226–230.
  27. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003; 290(21): 2831–2837.
  28. Wethal T, Lund MB, Edvardsen T, et al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer. 2009; 101(4): 575–581.
  29. Lund MB, Ihlen H, Voss BM, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart. 1996; 75(6): 591–595.
  30. Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015; 107(4).
  31. Crestanello JA, McGregor CGA, Danielson GK, et al. Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy. Ann Thorac Surg. 2004; 78(3): 826–31; discussion 826.
  32. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109(5): 1878–1886.
  33. Schneeberger Y, Seiffert M, Schaefer A, et al. TAVI for Pure Non-calcified Aortic Regurgitation Using a Self-Expandable Transcatheter Heart Valve. Front Cardiovasc Med. 2021; 8: 743579.
  34. McEniery PT, Dorosti K, Schiavone WA, et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987; 60(13): 1020–1024.
  35. Desai MY, Jellis CL, Kotecha R, et al. Radiation-Associated cardiac disease: a practical approach to diagnosis and management. JACC Cardiovasc Imaging. 2018; 11(8): 1132–1149.
  36. Desai MY, Wu W, Masri A, et al. Increased aorto-mitral curtain thickness independently predicts mortality in patients with radiation-associated cardiac disease undergoing cardiac surgery. Ann Thorac Surg. 2014; 97(4): 1348–1355.
  37. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
  38. Mohanty BD, Coylewright M, Sequeira AR, et al. Characteristics and clinical outcomes in patients with prior chest radiation undergoing TAVR: Observations from PARTNER-2. Catheter Cardiovasc Interv. 2022; 99(6): 1877–1885.
  39. Kogoj P, Devjak R, Bunc M. Balloon aortic valvuloplasty (BAV) as a bridge to aortic valve replacement in cancer patients who require urgent non-cardiac surgery. Radiol Oncol. 2014; 48(1): 62–66.
  40. Mantovani F, Clavel MA, Potenza A, et al. Balloon aortic valvuloplasty as a palliative treatment in patients with severe aortic stenosis and limited life expectancy: a single center experience. Aging (Albany NY). 2020; 12(16): 16597–16608.
  41. Glance LG, Lustik SJ, Hannan EL, et al. The Surgical Mortality Probability Model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg. 2012; 255(4): 696–702.
  42. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022; 43(39): 3826–3924.
  43. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6): 1374–1403.
  44. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012; 30(23): 2876–2884.
  45. Jaworski C, Mariani JA, Wheeler G, et al. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013; 61(23): 2319–2328.
  46. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012; 33(19): 2451–2496.
  47. Dimitrakakis G. Mini-AVR: An alternative safe treatment. Hellenic J Cardiol. 2021; 62(2): 167–168.
  48. Al Otaibi A, Gupta S, Belley-Cote EP, et al. Mini-thoracotomy vs. conventional sternotomy mitral valve surgery: a systematic review and meta-analysis. J Cardiovasc Surg (Torino). 2017; 58(3): 489–496.
  49. Toolan C, Palmer K, Al-Rawi O, et al. Robotic mitral valve surgery: a review and tips for safely negotiating the learning curve. J Thorac Dis. 2021; 13(3): 1971–1981.
  50. Chitwood WR, Nifong LW. Minimally invasive videoscopic mitral valve surgery: the current role of surgical robotics. J Card Surg. 2000; 15(1): 61–75.
  51. Grable C, Yusuf S, Song J, et al. Characteristics of infective endocarditis in a cancer population. Open Heart. 2021; 8(2): e001664.
  52. Mistiaen WP. A special topic in onco-cardiology: how to deal with a patient with endocarditis and malignancy. Future Cardiol. 2020; 16(2): 61–63.
  53. Pugalenthi LS, Ahmad M, Reddy S, et al. Malignancy and endocarditis: divulging into the intertwined association. Cureus. 2022; 14(4): e24089.
  54. Cosyns B, Roosens B, Lancellotti P, et al. Cancer and infective endocarditis: characteristics and prognostic impact. Front Cardiovasc Med. 2021; 8: 766996.
  55. Agnes A, Biondi A, Belia F, et al. Association between colorectal cancer and Streptococcus gallolyticus subsp. pasteuranus (former S. bovis) endocarditis: clinical relevance and cues for microbiota science. Case report and review of the literature. . Eur Rev Med Pharmacol Sci. 2021; 25(1): 480–486.
  56. Pericàs JM, Ambrosioni J, Muñoz P, et al. Prevalence of colorectal neoplasms among patients with enterococcus faecalis endocarditis in the GAMES cohort (2008-2017). Mayo Clin Proc. 2021; 96(1): 132–146.
  57. Sun LM, Wu JN, Lin CL, et al. Infective endocarditis and cancer risk: a population-based cohort study. Medicine (Baltimore). 2016; 95(12): e3198.
  58. Lee MH, Tsai WC, Su HM, et al. Nonbacterial thrombotic endocarditis in multiple heart valves. Kaohsiung J Med Sci. 2020; 36(3): 220–221.
  59. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015; 36(44): 3075–3128.
  60. Holle SL, Andersen MH, Klein CF, et al. Clinical usefulness of FDG-PET/CT for identification of abnormal extra-cardiac foci in patients with infective endocarditis. Int J Cardiovasc Imaging. 2020; 36(5): 939–946.
  61. Tyebally S, Chen D, Bhattacharyya S, et al. Cardiac tumors: state-of-the-art review. JACC CardioOncol. 2020; 2(2): 293–311.
  62. Watanabe Y, Kozuma K, Hioki H, et al. Comparison of results of transcatheter aortic valve implantation in patients with versus without active cancer. Am J Cardiol. 2016; 118(4): 572–577.
  63. Ngaage DL, Mullany CJ, Daly RC, et al. Surgical treatment of cardiac papillary fibroelastoma: a single center experience with eighty-eight patients. Ann Thorac Surg. 2005; 80(5): 1712–1718.
  64. DeMaria AN, Vismara LA, Miller RR, et al. Unusual echographic manifestations of right and left heart myxomas. Am J Med. 1975; 59(5): 713–720.
  65. Rhea IB, Lyon AR, Fradley MG. Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies. Curr Oncol Rep. 2019; 21(5): 45.
  66. D'Souza M, Carlson N, Fosbøl E, et al. CHADS-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018; 25(6): 651–658.
  67. López-Fernández T, Martín-García A, Rabadán IR, et al. Atrial fibrillation in active cancer patients: expert position paper and recommendations. RevEsp Cardiol (Engl Ed). . 2019; 72(9): 749–759.
  68. Saccullo G, Malato A, Raso S, et al. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. Am J Hematol. 2012; 87(4): 388–391.
  69. Murphy AC, Koshy AN, Cameron W, et al. Transcatheter aortic valve replacement in patients with a history of cancer: Periprocedural and long-term outcomes. Catheter Cardiovasc Interv. 2021; 97(1): 157–164.
  70. Kaihara T, Izumo M, Kameshima H, et al. Effect of Immunosuppressive Therapy on Clinical Outcomes for Patients With Aortic Stenosis Following Transcatheter Aortic Valve Implantation. Circ J. 2020; 84(12): 2296–2301.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl